Radius Health, Inc. (RDUS) CFO Jose Carmona Buys 3,000 Shares of Stock
Radius Health, Inc. (NASDAQ:RDUS) CFO Jose Carmona purchased 3,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were acquired at an average price of $32.83 per share, for a total transaction of $98,490.00. Following the purchase, the chief financial officer now owns 3,000 shares in the company, valued at $98,490. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Radius Health, Inc. (RDUS) traded up 1.67% on Friday, reaching $33.54. 2,925,848 shares of the company were exchanged. The firm’s market capitalization is $1.46 billion. Radius Health, Inc. has a 12-month low of $31.58 and a 12-month high of $59.22. The stock has a 50 day moving average of $37.32 and a 200 day moving average of $39.12.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.23). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same quarter last year, the firm posted ($1.01) EPS. Equities analysts anticipate that Radius Health, Inc. will post ($5.58) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/16/radius-health-inc-rdus-cfo-jose-carmona-buys-3000-shares-of-stock.html.
Several research analysts have recently commented on the stock. BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $53.60.
A number of institutional investors and hedge funds have recently modified their holdings of RDUS. BlackRock Inc. increased its holdings in Radius Health by 98,245.6% during the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after buying an additional 2,628,070 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after buying an additional 569,300 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in Radius Health during the second quarter worth $25,589,000. BB Biotech AG increased its holdings in Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after buying an additional 498,400 shares during the last quarter. Finally, RA Capital Management LLC acquired a new position in Radius Health during the second quarter worth $22,486,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.